Advos

DNA Damage Response inhibitors, led by PARP inhibitors, are expanding rapidly, with global sales over $7 billion in 2025, as new classes target DNA repair pathways and companies like Onco-Innovations advance nanoparticle-encapsulated PNKP inhibitors.

The Federal Reserve kept benchmark lending rates unchanged but signaled potential hikes later this year if inflation does not abate, citing uncertainty from high energy prices due to the Middle East conflict.

A new study reveals that artificial intelligence, while enhancing ecommerce convenience, is significantly undermining consumer trust, raising concerns for major platforms like Alibaba.

With the MiCA transition period ending on July 1, most crypto firms in the EU have yet to obtain full authorization under the new regulatory framework, potentially impacting major players like Coinbase.

Nocera provides details on its minority equity investment in CampaignPulse.ai, an AI-driven platform for simulating audience responses and testing messaging strategies, complementing its broader AI strategy.

A press release highlights that about 90% of men undergoing prostate cancer treatment and nearly 50% of men treated for other cancers experience sexual dysfunction, yet most never seek help, despite available solutions.

The United States now has over 250,000 public electric vehicle charging ports across roughly 80,500 sites, marking a critical milestone that supports broader EV adoption and could benefit domestic manufacturers like Lucid Motors.

Nvidia CEO Jensen Huang argues that the next phase of AI will strengthen American manufacturing and create job opportunities, countering fears of job displacement.

Nightfood Holdings Inc., through its TechForce Robotics division, is expanding its AI-enhanced robotics platform beyond hospitality into pharmaceutical, laboratory, and semiconductor-adjacent manufacturing, capitalizing on the global AI infrastructure buildout.

I Bonds, U.S. government-backed savings securities, currently pay a 4.26% composite rate for bonds issued through October 2026, highlighting their role as a low-risk inflation hedge.

LaFleur Minerals is set to restart production at its Beacon Gold Mill in the Abitibi Gold Belt, leveraging a bulk sample from the Swanson Gold Project for its first gold pour as gold prices remain high.

Foreign investors purchased a net $206 billion of long-term U.S. securities in April, indicating sustained demand for U.S. assets amid discussions on reserve diversification.

Xeriant (OTCQB: XERI) is moving toward commercial production of its NEXBOARD composite building panels after achieving key fire safety certifications, with a production run to supply samples to leading homebuilders and commercial construction firms.

M-tron Industries received a $6.8 million follow-on order from a U.S. Department of Defense contractor to supply components for counter-unmanned aircraft system radar programs, with work through 2027 and production expected beyond 2030.

Knight Therapeutics repaid the full $60 million drawn from its credit facility to fund the Paladin acquisition, using operational cash flow, while maintaining access to $200 million in borrowing capacity for future growth.

Onco-Innovations Limited announced a C$5 million private placement to fund manufacturing and preclinical testing of its ONC010 cancer treatment and SynoGraph platform.

Silvercorp Metals Inc. has filed an updated NI 43-101 technical report for its Ying Ag-Pb-Zn-Au Property in China, confirming no material changes from its June 2026 resource update.

Onco-Innovations Limited announced a successful 300-gram scale-up batch of its ONC010 drug candidate with 99.3% purity and appointed Dave Antony as CFO, advancing its cancer treatment pipeline.

VERAXA Biotech AG presents partnering opportunities for its BiTAC-ADC and BiTAC-TCE platforms, backed by new proof-of-concept data showing tumor-restricted activation and reduced toxicity, potentially applicable to multiple solid tumors.

VERAXA Biotech AG is showcasing its proprietary BiTAC-ADC and BiTAC-TCE platforms at the upcoming BIO International Convention, backed by new proof-of-concept data, signaling potential partnering opportunities for cancer therapy development.

Redwood AI Corp. has initiated a Chemical Risk Assessment Module within its Reactosphere platform and appointed Stanford chemistry professor Dr. Noah Burns as scientific advisor to enhance chemical safety and AI-driven chemistry research.